daily subcutaneous injection of 0.2 ml of the vitamin-Dz
inhibited in group C rats by the addition of chlorothiazide, which restored urinary calcium excretion to 6.8 + 2.5 mg/kg/day ( p < confirmed these effects of vitamin-D2 and chlorothiazide on urine calcium excretion. We conclude that in rats conventional doses of vitamin-D2 consistently induce marked hypercalciuria, even witbout hypercalcemia, and that this hypercalciuria can be effectively prevented by chlorothiazide. vehicle only; Group B, the vitamin-Dz group was composed of six rats that were injected daily subcutaneously with 50 IU of vitamin-DP (Drisdol, Winthrop Laboratories, New York, NY); and Group C, the vitamin-Dz and chlorothiazide group included six rats that were treated in the same manner as those in Group B but additionally with chlorothiazide 20 mg/day injected intraperitoneally (Diuril, Merck Sharp and Dohme, West Point, PA) for the last six days. During the last 3 days of the study all urine was collected, mixed, and measured. At the end of the study a blood sample was obtained from each rat by aortic puncture.
The urine was analyzed for calcium, creatinine, and sodium, and the serum for calcium and creatinine. Calcium was determined by atomic absorption spectrophotometry, nonchromogen creatinine, and sodium by standard methods. Student's t test was used to determine the significance of the difference between the groups. renal calcium excretion in both humans and research animals (7, B, vitamin-D2.
13, 16, 23). They have been widely used for more than 15 years to
treat hypercalciuric patients (5, 24) . Previous attempts to evaluate the effect of thiazides on vitamin-D-induced hypercalciuria have RESULTS produced the conflicting claims that urine calcium excretion is reduced in some patients (12, 18) but that it is not reduced in All rats consumed 16 2 g of the Purina chow and lost 2.1 * others (3, 19, 24) . It has, therefore, been recommended that further 1.2% of their weight during the 12-day study, with no difference studies are needed ( I 1). between the groups. As shown in Table 1 , no significant differIn the controlled study presented below, we tested the effects of mces appeared between the groups also for serum and chlorothiazide on vitamin-Dz-induced hypercalciuria in rats.
creatinine concentrations or for glomerular filtration rates as expressed by creatinine clearance. Administration of vitamin-Dz,
MATERIALS AND METHODS
however, affected a 3-fold increase in the mean rate of daily urine calcium excretion (Table 2) ; an increase that remained significant Seventeen metabolic studies were conducted in adult Sprague-when the calcium excretion was also considered relative to urinary Dawley male rats, weighing 465 + 30 g, which were maintained creatinine and urinary sodium excretion rates (Table 2) . Chloroin metabolic cages with free access to water, on a standard thiazide, administered to group C rats during the last 6 days, commercial Purina chow diet. After 1 wk of equilibration, the inhibited the calciuric effects of vitamin-DZ and returned the animals were randomly assigned to one of three groups for a 12-calcium excretion rate to its control values. No significant differday study as follows:
ences in calcium excretion were found between the control group Group A, the control group, comprised five rats that received and the thiazide-treated group at the end of the study. (4, 11, 15) , and thus may sometimes promote nephrolithiasis, nephrocalcinosis, and deterioration in kidney functions (1 1). The present study demonstrates that vitamin-DZ administered to rats for 12 days at a dose similar to that in clinical use for human beings, results in a 3-fold increase in the mean daily urinary calcium excretion (Table 2 ). When we tested the influences of other factors, such as body mass, fluid-electrolyte balance, and diet on calcium excretion, by evaluating the interrelationships between urine calcium and creatinine or sodium excretion (1 l, 22), the relative increases in calcium excretion remained consistently significant ( Table 2) .
We also confirmed (Table 1 ) the earlier observations of Litvak et al. (14) that vitamin-D-induced hypercalciuria can occur without concomitant hypercalcemia, an effect we have recently demonstrated (4) in children with sex-linked dominant hypophosphatemic rickets treated by 1,25-dihydroxyvitamin-D3. The hypercalciuria brought about by vitamin-D metabolites administration is believed to be secondary to enhanced intestinal calcium absorption, an elevated filtered load of ionized calcium, and depressed serum parathyroid hormone (20) . The stability of glomerular filtration rates in our study (Table 1) is important, because other parameters such as phosphaturia and acid-base disorders that might be implicated in the calciuria are dependent on changes in glomerular filtration rates. Furthermore, because hypercalcemia can cause kidney function deterioration with concomitant elevation in serum creatinine concentration (1 I), the maintenance of normal serum calcium concentration in our rats is reflected in the stability of their serum creatinine and creatinine clearances.
The administration of thiazides, well-known as hypocalciuric agents (5, 23, 24) , to patients with vitamin-D-induced hypercalciuria is a matter of some controversy. Parfitt (18) and Higgins et al. (12) reported that thiazides were effective in decreasing the amount of calcium in the urine of vitamin-D-treated patients. Yendt and Cohanim (24) , Parfitt (19) , and Brickman et al. (3) , who studied patients with hypoparathyroidism treated by vitamin-D, found that thiazide had no influence on the excretion of calcium; on the other hand, normal controls receiving vitamin-D studied by the last group (3) experienced reduction in calcium excretion rates under treatment. Harrison and Harrison (11) pressed for further controlled studies of thiazide therapy for vitamin-D-induced hypercalciuria before conclusions should be drawn about their applicability in man.
Previous studies in the dog (7) and the rat (13, 16) have demonstrated the effectiveness of thiazides in decreasing urinary calcium excretion, but did not study the specific action of the thiazides in hypercalciuria caused by vitamin-D. The ability of chlorothiazide to reverse vitamin-Dz-induced hypercalciuria and effect a decrease in calcium excretion to control values in rats is clearly demonstrated in the present study (Table 2 ).
An absence of hypercalcemia induction and a persistence of stable serum creatinine and creatinine clearance accompanied the treatment (Table 1) . A mild but still insignificant increase in serum calcium concentration was also observed by Jorgensen (13) when he treated normal Wistar rats with bendroflumethiazide.
As has been domonstrated previously, there are two mechanisms by which the thiazides reduce calcium excretion: (1) by the decrease in extracellular fluid volume and hence by nonspecific stimulation of the sodium-coupled calcium reabsorption in the proximal tubule (2, 3, 21) and (2) by specific dissociative action on the distal tubule, which results in enhanced reabsorption of calcium in contrast to decreased reabsorption of sodium (6, 8, 9) . This dissociation of calcium/sodium reabsorptions is also evident in the present study (Table 2) , as the ratio of urine calcium excretion to urine sodium excretion decreased with chlorothiazide administration.
In summary, we conclude that in rats (I), vitamin-Dz administration in conventional doses induces marked hypercalciuria that is independent of serum calcium concentration, creatinine clearance, or the urine excretion of sodium and (2) that administration of chlorothiazide effectively prevents and precludes hypercalciuria presumably by acting directly to augment tubular calcium reabsorption, without changes in the glomerular filtration rates or in serum calcium concentration.
